"INTREPID Results Support Livalo As Optimal Treatment For HIV Patients With Dyslipidemia"
Because patients with HIV are living longer due to recent advances in treatment, other health issues such as cardiovascular disease are becoming more evident in this population. According to Judith A. Aberg, MD, chief of the division of infectious diseases and immunology at the Icahn School of Medicine at Mount Sinai, "The risk for myocardial infarction is 1.5 to 2 times higher in people living with HIV compared with uninfected individuals. In addition, dyslipidemia has been reported in up to 80% of patients with HIV. Although statin therapy is typically recommended for the condition, it has been a challenge to implement in this population because of adverse drug interactions with ART, which can sometimes lead to intolerance or reduced efficacy."
- Judith Aberg, MD, Dr. George Baehr Professor, Medicine, Infectious Disease, Chief, Division of Infectious Diseases and Immunology, Icahn School of Medicine at Mount Sinai